Harrow says QUELL trial of IHEEZO posts topline data in Q4 2026

Harrow highlighted new clinical and real-world evidence for IHEEZO and BYOOVIZ presented at the ASRS 2026 annual meeting.

Interim results from a randomized study suggested IHEEZO could improve post-injection comfort and overall patient experience versus a common anesthetic approach.

A large retrospective review found no signal that IHEEZO’s gel formulation increased infection risk when used with a chlorhexidine-based antisepsis routine.

The QUELL randomized, multi-center trial remains ongoing, with topline results expected in Q4 2026.

Interim findings from a large real-world post-marketing surveillance study of BYOOVIZ were also presented at the meeting.